12th Oct 2016 16:58
12 October 2016
LSE: VER
Vernalis plc
Director/PDMR Dealing
Vernalis plc (LSE: VER) ("the Company") announces that David Mackney, Chief Financial Officer of the Company was today allotted 48,630 ordinary shares of 1 pence each ("Ordinary Shares") following his exercise of options under the Company's 2007 Bonus Long-Term Incentive Plan ("LTIP"). Mr Mackney subsequently sold 27,233 Ordinary Shares to settle payment of all tax and NI requirements in relation to the exercise as set out in the notification below.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1. | Details of PDMR / person closely associated with them ("PCA") | |||||
a) | Name | David Mackney | ||||
2. | Reason for the notification | |||||
a) | Position / status | Chief Financial Officer | ||||
b) | Initial notification / amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Vernalis plc | ||||
b) | Legal Entity Identifier | n/a | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 1 pence each ("Ordinary Shares") GB00B3Y5L754 | ||||
b) | Nature of the transaction | Exercise and Allotment of Ordinary Shares under the Company's LTIP | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Aggregated price - Aggregated total |
N/A - single transaction | ||||
e) | Date of the transaction | 12 October 2016 (UK) | ||||
f) | Place of the transaction | Outside a trading venue | ||||
5. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument Identification code | Ordinary shares of 1 pence each ("Ordinary Shares") GB00B3Y5L754 | ||||
b) | Nature of the transaction | Sale of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Aggregated price - Aggregated total |
N/A - single transaction | ||||
e) | Date of the transaction | 12 October 2016 (UK) | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
-- ends -
Enquiries:
Vernalis plc: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer | |
David Mackney, Chief Financial Officer
| |
Canaccord Genuity Limited (Nominated Adviser and Joint Broker): | +44 (0) 20 7523 8000 |
Dr Julian Feneley | |
Rupert Winckler | |
Henry Fitzgerald-O'Connor | |
Emma Gabriel
| |
Shore Capital (Joint Broker): | +44 (0)20 7408 4090 |
Bidhi Bhoma | |
Toby Gibbs
| |
FTI Consulting: | +44 (0) 20 3727 1000 |
Ben Atwell | |
Simon Conway |
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra® XR, targeting the US prescription cough-cold market; Moxatag®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho, and Tris.
For further information about Vernalis, please visit www.vernalis.com.
Related Shares:
Vernalis PLC